Medical Therapy for Heart Failure with Preserved Ejection Fraction
References
- Pfeffer MA, Shah AM, Borlaug BA. Heart Failure With Preserved Ejection Fraction In Perspective. Circ Res. 2019 May 24;124(11):1598–1617. doi: 10.1161/CIRCRESAHA.119.313572
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895–e1032. doi: 10.1161/CIR.0000000000001063
- Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med. 2004;55:373–94. doi: 10.1146/annurev.med.55.091902.104417
- Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000 May 2;101(17):2118–21. doi: 10.1161/01.cir.101.17.2118
- Parikh KS, Sharma K, Fiuzat M, et al. Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. JACC Heart Fail. 2018 Aug;6(8):619–632. doi: 10.1016/j.jchf.2018.06.008
- Hahn VS, Yanek LR, Vaishnav J, et al. Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. JACC Heart Fail. 2020 Sep;8(9):712–724. doi: 10.1016/j.jchf.2020.04.007
- Oghina S, Bougouin W, Bezard M, et al. The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials. JACC Heart Fail. 2021 Mar;9(3):169–178. doi: 10.1016/j.jchf.2020.12.005
- Hussain N, Charalampopulos A, Ramjug S, et al. Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management. Pulm Circ 2016;6(1):3–14. doi: 10.1086/685021
- Humbert M, Kovacs G, Hoeper M, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Aug 26;43:3618–3731. doi: 10.1093/eurheartj/ehac237
- Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018 Aug 28;138(9):861–870. doi: 10.1161/CIRCULATIONAHA.118.034646
- Sepehrvand N, Alemayehu W, Dyck GJB, et al. External Validation of the H2F-PEF Model in Diagnosing Patients With Heart Failure and Preserved Ejection Fraction. Circulation. 2019 May 14;139(20):2377–2379. doi: 10.1161/CIRCULATIONAHA.118.038594
- CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 4;316(23):1429–35. doi: 10.1056/NEJM198706043162301
- Cohn JN, Archibald DG, Ziesche P, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986 Jun 12;314(24):1547–52. doi: 10.1056/NEJM198606123142404
- Cohn J, Johnson G. Heart failure with normal ejection fraction. The V-HeFT Study. Veterans Administration Cooperative Study Group. Circulation. 1990 Feb;81(2 Suppl):III48–53
- Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145–53. doi: 10.1056/NEJM200001203420301
- Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003 Sep 6;362(9386):777–81. doi: 10.1016/S0140-6736(03)14285-7
- Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 4;359(23):2456–67. doi: 10.1056/NEJMoa0805450
- Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018 Aug;20(8):1230–1239. doi: 10.1002/ejhf.1149
- Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J.; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006 Oct;27(19):2338–45. doi: 10.1093/eurheartj/ehl250
- Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 Apr 10;370(15):1383–92. doi: 10.1056/NEJMoa1313731
- Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015 Jan 6;131(1):34–42. doi: 10.1161/CIRCULATIONAHA.114.013255
- Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012 Oct 20;380(9851):1387–95. doi: 10.1016/S0140-6736(12)61227-6
- Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 Oct 24;381(17):1609–1620. doi: 10.1056/NEJMoa1908655
- Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 3;364(9):797–805. doi: 10.1056/NEJMoa1005419
- Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011 Feb 19;377(9766):658–66. doi: 10.1016/S0140-6736(11)60101-3
- Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021 Sep 11;398(10304):991–1001. doi: 10.1016/S0140-6736(21)01754-2
- Anker S, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Oct 14;385(16):1451–1461. doi: 10.1056/NEJMoa2107038
- Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021 Nov;27(11):1954–1960. doi: 10.1038/s41591-021-01536-x
- Cunningham JW, Vaduganathan M, Claggett BL, et al. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. 2022 Oct 4;80(14):1302–1310. doi: 10.1016/j.jacc.2022.07.021
- Sawicki KT, Ben-Sahra I, McNally EM. SGLT2 Inhibition on Cardiac Mitochondrial Function: Searching for a Sweet Spot. J Am Heart Assoc. 2021 Jul 6;10(13):
e021949 . doi: 10.1161/JAHA.121.021949 - Heerspink HJL, Stefansson BV, Correa-Rotter R, et al.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436–1446. doi: 10.1056/NEJMoa2024816
- Butler J, Zannad F, Fitchett D, et al. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. Circ Heart Fail. 2019 Jun;12(6):
e005875 . doi: 10.1161/CIRCHEARTFAILURE.118.005875
DOI: https://doi.org/10.14797/mdcvj.1162 | Journal eISSN: 1947-6108
Language: English
Page range: 17 - 26
Submitted on: Sep 15, 2022
Accepted on: Nov 8, 2022
Published on: Dec 6, 2022
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2022 Sara Varnado, Hyeon-Ju Ryoo Ali, Barry Trachtenberg, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.